Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19066731 | 1.00 | CTSK (0.46) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL18248083 | 1.00 | CTSK (0.46) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL21447947 | 1.00 | CTSK (0.46) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL21447763 | 1.00 | CTSK (0.46) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL13519510 | 0.92 | CTSK (0.48) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL27853178 | 0.92 | CTSK (0.48) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL22651717 | 0.90 | CTSK (0.41) | CTSKCTSBCTSLCTSSAAK1 | |
| SCHEMBL23269885 | 0.89 | MMP13 (0.39) | CTSKCTSBCTSLCTSSREN | |
| SCHEMBL18248147 | 0.89 | MMP13 (0.39) | CTSKCTSBCTSLCTSSREN | |
| SCHEMBL18248145 | 0.89 | MMP13 (0.39) | CTSKCTSBCTSLCTSSREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676265-B1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-08-20 | — | — | EP | disclosed |
| EP-3790876-B1 | ENDOPARASITIC DEPSIPEPTIDES | ZOETIS SERVICES LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250019360-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-01-16 | — | — | US | disclosed |
| US-12122759-B2 | Method for the synthesis of cyclic depsipeptides | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-22 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-112384511-B | Endoparasite depsipeptides | 硕腾服务有限责任公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11786575-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3397638-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Merial, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2016187534-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CTSK 185/4885CTSB 118/4885CTSL 129/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | CTSK 111/4885CTSB 78/4885CTSL 77/4885 |
| US-20170022253-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSK 204/4885CTSB 101/4885CTSL 86/4885 |
| US-11786575-B2 | Endoparasitic depsipeptides | VIP, PREP, NGLY1 | CTSK 518/4885CTSB 143/4885CTSL 75/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | CTSK 185/4885CTSB 118/4885CTSL 129/4885 |
| US-12122759-B2 | Method for the synthesis of cyclic depsipeptides | DNPEP, NPEPPS, PREP | CTSK 669/4885CTSB 690/4885CTSL 799/4885 |
| US-20250019360-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | DNPEP, NPEPPS, PREP | CTSK 669/4885CTSB 690/4885CTSL 799/4885 |
| US-12286455-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | CTSK 204/4885CTSB 101/4885CTSL 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.